STERIS Competitors

Abbott Laboratories (NYSE:ABT) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 90.0% of STERIS shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by company insiders. Comparatively, 1.2% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Abbott Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. STERIS pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and STERIS has increased its dividend for 14 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Abbott Laboratories and STERIS, as provided by MarketBeat.

Abbott Laboratories currently has a consensus price target of $115.6875, suggesting a potential upside of 0.84%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and STERIS's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Abbott Laboratories and STERIS's top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Abbott Laboratories beats STERIS on 11 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

79.2% of Medtronic shares are owned by institutional investors. Comparatively, 90.0% of STERIS shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 1.2% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.0%. STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Medtronic pays out 50.5% of its earnings in the form of a dividend. STERIS pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 44 consecutive years and STERIS has raised its dividend for 14 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Medtronic and STERIS, as provided by MarketBeat.com.

Medtronic presently has a consensus price target of $122.2963, suggesting a potential upside of 4.62%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's higher possible upside, analysts plainly believe STERIS is more favorable than Medtronic.

Profitability

This table compares Medtronic and STERIS's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Medtronic and STERIS's gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than STERIS. Medtronic is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Summary

Medtronic beats STERIS on 10 of the 18 factors compared between the two stocks.

Stryker (NYSE:SYK) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Insider and Institutional Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 90.0% of STERIS shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 1.2% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Stryker has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Stryker pays out 30.5% of its earnings in the form of a dividend. STERIS pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and STERIS has raised its dividend for 14 consecutive years.

Analyst Ratings

This is a summary of current ratings and recommmendations for Stryker and STERIS, as provided by MarketBeat.com.

Stryker presently has a consensus price target of $227.4783, suggesting a potential downside of 5.04%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Stryker.

Profitability

This table compares Stryker and STERIS's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Stryker and STERIS's gross revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than STERIS. Stryker is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats STERIS on 11 of the 18 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Risk and Volatility

Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are held by institutional investors. Comparatively, 90.0% of STERIS shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by insiders. Comparatively, 1.2% of STERIS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Intuitive Surgical and STERIS's gross revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and STERIS's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Intuitive Surgical and STERIS, as provided by MarketBeat.com.

Intuitive Surgical presently has a consensus price target of $736.0588, suggesting a potential downside of 2.12%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats STERIS on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Dividends

Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.3%. STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. STERIS pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has raised its dividend for 48 consecutive years and STERIS has raised its dividend for 14 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Becton, Dickinson and has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Institutional and Insider Ownership

83.2% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 90.0% of STERIS shares are held by institutional investors. 0.8% of Becton, Dickinson and shares are held by insiders. Comparatively, 1.2% of STERIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Becton, Dickinson and and STERIS's gross revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than STERIS. Becton, Dickinson and is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and and STERIS's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Becton, Dickinson and and STERIS, as provided by MarketBeat.com.

Becton, Dickinson and presently has a consensus price target of $279.6667, suggesting a potential upside of 7.46%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than Becton, Dickinson and.

Summary

STERIS beats Becton, Dickinson and on 9 of the 17 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 90.0% of STERIS shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.2% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Edwards Lifesciences and STERIS's gross revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and STERIS's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Edwards Lifesciences and STERIS, as provided by MarketBeat.com.

Edwards Lifesciences presently has a consensus price target of $90.8704, suggesting a potential upside of 5.80%. STERIS has a consensus price target of $210.00, suggesting a potential upside of 10.29%. Given STERIS's stronger consensus rating and higher possible upside, analysts clearly believe STERIS is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats STERIS on 10 of the 14 factors compared between the two stocks.